32nd week of 2022 patent applcation highlights part 10 |
Patent application number | Title | Published |
20220249492 | ANTICANCER COMBINATION THERAPY - The invention describes anti-cancer therapies comprising using a SOS1 inhibitor in combination with a MEK inhibitor, each as described herein. | 2022-08-11 |
20220249493 | PHARMACEUTICAL COMPOSITION COMPRISING UDENAFIL - A pharmaceutical composition comprising udenafil is disclosed. | 2022-08-11 |
20220249494 | USE OF INHIBITORS OF BRUTONS TYROSINE KINASE (BTK) - Disclosed herein are methods for treating a cancer comprising: a. administering a Btk inhibitor to a subject sufficient to result in an increase or appearance in the blood of a subpopulation of lymphocytes defined by immunophenotyping; b. determining the expression profile of one or more biomarkers from one or more subpopulation of lymphocytes; and c. administering a second agent based on the determined expression profile. | 2022-08-11 |
20220249495 | Dosing Regimens Associated With Extended Release Paliperidone Injectable Formulations - The present invention provides a method of treating patients with long acting injectable paliperidone palmitate formulations. | 2022-08-11 |
20220249496 | TOPICAL ACYCLOVIR FORMULATIONS AND USES THEREOF - Provided herein are gel formulations of acyclovir with a low concentration of acyclovir, which can be used, for example, for the treatment of recurrent herpes labialis (cold sores) in immunocompetent adults and adolescents 12 years of age and older. The gel formulation can be an aqueous gel formulation, an emulsified gel formulation, or a non-aqueous gel formulation. | 2022-08-11 |
20220249497 | COMPOSITIONS AND METHODS FOR IMPROVING RELAXATION, SLEEP, COGNITION, AND/OR PHYSICAL PERFORMANCE - Cognitive and/or physical performance may be improved by administering a therapeutically effective amount of 1,3-butanediol, selected from R-1,3-butanediol, S-1,3-butanediol, and racemic 1,3-butanediol, in combination with a therapeutically effective amount of one or more additional active ingredients selected from caffeine, L-theanine, and a mixture of caffeine and L-theanine. Relaxation and/or sleep performance may be improved by administering a therapeutically effective amount of 1,3-butanediol, selected from R-1,3-butanediol, S-1,3-butanediol, and racemic 1,3-butanediol, in combination with a therapeutically effective amount of L-theanine. The disclosed compositions include synergistically effective amounts of 1,3-butanediol in combination with a synergistically effective amount of caffeine, L-theanine, and a mixture of caffeine and L-theanine. The compositions may be administered to a subject for improving relaxation, sleep, cognition, and/or physical performance in the subject. | 2022-08-11 |
20220249498 | TABLET FORMULATION OF 2-FLUORO-N-METHYL-4-[7-(QUINOLIN-6-YLMETHYL)IMIDAZO[1,2-B][1,2,4]TRIAZIN-- 2-YL]BENZAMIDE - The present invention is related to tablets comprising of 2-fluoro-N-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide, processes for the production thereof, and uses in the treatment of certain cancers. | 2022-08-11 |
20220249499 | METABOLITES OF BICTEGRAVIR - The present invention provides metabolites of the antiviral drug bictegravir, including compositions and salts thereof, which are useful in the prevention and/or treatment of HIV as well as analytical methods related to the administration of bictegravir. | 2022-08-11 |
20220249500 | PHENOXY(HETERO)ARYL ETHERS OF ANTIPROLIFERACTIVE ACTIVITY - The present invention comprises novel aromatic molecules, which can be used in the treatment of pathological conditions, such as cancer, skin diseases, muscle disorders, and immune system-related disorders such as disorders of the haematopoietic system including the haematologic system in human and veterinary medicine. | 2022-08-11 |
20220249501 | USE OF ESREBOXETINE TO TREAT NERVOUS SYSTEM DISORDERS SUCH AS FIBROMYALGIA - Described herein are methods of treating narcolepsy with cataplexy, comprising administering reboxetine (including esreboxetine) to a human being in need thereof. Reboxetine (including esreboxetine) may also be used in the manufacture of a medicament for the treatment of narcolepsy with cataplexy. Also disclosed herein are kits comprising a pharmaceutical composition comprising reboxetine (including esreboxetine) and instructions to use the pharmaceutical composition to treat narcolepsy with cataplexy in a human being. | 2022-08-11 |
20220249502 | COMBINATION THERAPY WITH A PHOSPHOINOSITIDE 3-KINASE INHIBITOR WITH A ZINC BINDING MOIETY - The invention provides a method of treating cancer in a subject in need thereof, comprising administering to the subject:
| 2022-08-11 |
20220249503 | TRANSDERMAL PERMEATION ENHANCING COMPOSITION AND APPLICATION THEREOF IN TIMOLOL PREPARATION - A transdermal permeation enhancing composition, consisting of 65 wt %-98 wt % of white vaseline and 2 wt %-35 wt % of wax substance. The wax substance is selected from one or more of light liquid paraffin and white beeswax. The transdermal permeation enhancing composition is used for improving the transdermal absorption effect of timolol. | 2022-08-11 |
20220249504 | LONGEVITY SIGNATURES AND THEIR APPLICATIONS - The present disclosure relates to compositions and methods useful for elongating the lifespan of a subject (e.g., a mammalian subject, such as a human). Additionally or alternatively, the compositions and methods of the disclosure can be used to treat, prevent, and/or delay the onset of various geriatric syndromes in such a subject. The disclosure also provides compositions and methods that can be used to identify new interventions, such as chemical agents, lifestyle changes, or diets, that can be used to increase lifespan and to treat, prevent, and/or delay the onset of geriatric syndromes. | 2022-08-11 |
20220249505 | APPETITE SUPPRESSANT COMPOSITIONS AND METHODS THEREOF - An appetite suppressant composition may comprise at least one anorectic active ingredient; at least one of a nutritive substance, a cofactor; and optionally, an excipient. The anorectic active ingredient may comprise any one of phentermine, phendimetrazine, diethylpropion, naltrexone, and bupropion. The nutritive substance may comprise a protein source such as bovine collagen. The cofactor may comprise a chromium or selenium salt. In various embodiments, the compositions herein are provided in an oral capsule dosage form for GI-tract administration of the AAI. A method of suppressing appetite in individuals in need thereof are described. | 2022-08-11 |
20220249506 | Meloxicam-Containing Granulated Product - To provide a technique for improving the dissolution of meloxicam. A granulated product, including the following components (A), (B), and (C): (A) meloxicam or a salt thereof, or a solvate thereof; (B) one or more basic compounds selected from the group consisting of potassium bicarbonate, sodium bicarbonate, arginine, lysine, magnesium hydroxide, and magnesium oxide; and (C) a water-swellable polymer. | 2022-08-11 |
20220249507 | PHARMACEUTICAL LIQUID COMPOSITIONS OF MELOXICAM - The present invention relates to stable injectable compositions comprising meloxicam or its pharmaceutically acceptable salts, solvates, or hydrates thereof, wherein the composition is provided in a sealed container, e.g., an ampoule, vial and pre-filled syringe. Further, the present invention relates to a stable injectable solution comprising meloxicam or its pharmaceutically acceptable salts, solvates, or hydrates thereof, suitable for subcutaneous, intravenous or intramuscular administration. The invention relates to methods for manufacturing stable injectable solutions of meloxicam. The present invention further relates to a method of treating pain by parenterally administering to a patient in need thereof a composition comprising a stable solution of meloxicam, wherein said solution provides rapid onset of action for pain relief compared to a reference composition. | 2022-08-11 |
20220249508 | VARENICLINE COMPOUND AND PROCESS OF MANUFACTURE THEREOF - The present disclosure relates to the field of synthesizing substantially pure varenicline and its intermediates. It also relates to the pharmaceutical compositions comprising varenicline and the method of use of these pharmaceutical compositions for smoking cessation. | 2022-08-11 |
20220249509 | METHOD FOR PREVENTING HAIR LOSS - Methods and compositions useful in the prevention and treatment of hair loss. In some embodiments, compositions are applied to hair follicles to inhibit the transition of growth phases. In some embodiments, the composition is a myosin light chain kinase (MLCK) inhibitor alone, or in conjunction with other components. In some embodiments, methods are disclosed for identifying and/or selecting compositions for use in methods of preventing or treating hair loss. | 2022-08-11 |
20220249510 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR ANESTHESIOLOGICAL APPLICATIONS - Pharmaceutical compositions and methods for inducing conscious sedation using such compositions are described, the compositions including a benzodiazepine-based compound, an NMDA antagonist, and optionally a β-blocker, antiemetic, an NSAID, and/or an antihistamine medication. Compositions may be incorporated into vehicles for extended release. Methods for fabricating the compositions and using them for anesthesiological applications are also described. | 2022-08-11 |
20220249511 | METHODS FOR THE TREATMENT OF KELOID, HYPERTROPHIC SCARS AND/OR HYPERPIGMENTATION DISORDERS - The invention relates to a PI3K inhibitor for use in the treatment of keloid, hypertrophic, bum scars and/or hyperpigmentation disorders in a subject in need thereof. 19 patients underwent multiple surgeries before receiving BYL719. These surgery procedures led to a certain number of severe hypertrophic and keloid scars. Inventors observed that during treatment with oral BYL719, the length, the area and the thickness of the different scars were dramatically reducing without additional treatment. Furthermore, they observed a spontaneous that the nevi were spontaneously decolorating with BYL719. Nevus color was evaluated using an arbitrary visual scale ranging from (5: dark color to 1: normal skin color). This new approach with either BYL719 alone or in combination with other therapeutics seem to be very promising in patients with keloid, hypertrophic, and/or burn scars. | 2022-08-11 |
20220249512 | TOPICAL PHARMACEUTICAL COMPOSITIONS COMPRISING DILTIAZEM - The present invention provides a diltiazem preparation for treatment for anal fissures, hemorrhoids, or other benign anal disorders wherein the preparation is applied topically directly to the affected area and thereby reduces swelling, inflammation, pain and promotes healing. | 2022-08-11 |
20220249513 | ACTIVITY OF GOLD-COMPLEXED COMPOUNDS AGAINST MYCOBACTERIUM TUBERCULOSIS AND MYCOBACTERIUM ABSCESSUS - Disclosed herein are gold compounds and methods of use thereof as antibacterials. Specifically exemplified are methods of treating a | 2022-08-11 |
20220249514 | REMEDY FOR HAIR GROWTH ENHANCING - The invention relates to the field of cosmetology, dermatology and medicine, and is concerned with the development and production of a combination, and also of a composition based thereon, for hair growth enhancing in mammals and/or for preventing and/or treating alopecia, primarily in humans, and more particularly to combinations based on derivatives of F- and E-type prostaglandins, characterized by the absence of undesirable side-effects, and also to a stable composition comprising said combination. The use of a combination of prostaglandins in a single composition makes it possible to simultaneously activate a plurality of physiological processes, including stimulating a hair follicle to produce a new hair, increasing the local microcirculation in the area adjacent to the hair follicle, and reducing the aggregation of thrombocytes, thereby preventing thrombogenesis in the capillary network. Furthermore, the presence in the combination or in the composition based thereon of modified prostaglandins carrying a group of nitrogen oxide donors enables better penetration of other ingredients of the combination or composition into the skin. | 2022-08-11 |
20220249515 | GANAXOLONE FOR USE IN TREATING GENETIC EPILEPTIC DISORDERS - The disclosure provides a method of treating a mammal having a genetic epileptic disorder, comprising chronically administering a pharmaceutically acceptable pregnenolone neurosteroid to a mammal having a genetic epileptic disorder in an amount effective to reduce the seizure frequency in the mammal. In certain preferred embodiments, the mammal is a human patient who has a CDKL5 genetic mutation. In certain preferred embodiments, the patient has a low endogenous level of a neurosteroid(s). In certain preferred embodiments, the pregnenolone neurosteroid is ganaxolone. | 2022-08-11 |
20220249516 | Optimizing Mifepristone Absorption - The present invention provides a method for altering the pharmacokinetics of mifepristone upon oral administration. Mifepristone absorption into the blood is increased upon administration with meals. The method of the invention can benefit patients suffering from conditions including psychiatric illnesses and hormonal disorders. | 2022-08-11 |
20220249517 | COMPOSITIONS AND METHODS FOR TREATING NONINFECTIOUS UVEITIS - The present invention relates to methods, devices, and compositions for treating ocular disorders such as uveitis, macular edema associated with uveitis, and diabetic macular edema. For example, the methods include treatment of subjects having macular edema associated with non-infectious uveitis, or diabetic macular edema, by administering to the subjects a triamcinolone composition via non-surgical administration to the suprachoroidal space (SCS) of the eye. | 2022-08-11 |
20220249518 | USE OF OUABAIN ANTAGONISTS TO INHIBIT VIRAL INFECTION - Embodiments of a method for inhibiting viral infection in a subject are provided herein. In some embodiments, the method comprises administration of a competitive antagonist of ouabain binding to ATP1A1 to inhibit respiratory syncytial virus infection in the subject. | 2022-08-11 |
20220249519 | COMPOSITIONS OF HYDROXY ACIDS WITH SALICYLIC ACID AND USES THEREFORE - The present disclosure generally relates to topical compositions comprising a combination of at least one alpha-hydroxy acid (e.g., glycolic acid) combined with at least one beta-hydroxy acid (e.g., salicylic acid) in the presence of water-soluble polystyrenes or appropriate salts thereof. The present disclosure further provides methods of making and using such compositions. | 2022-08-11 |
20220249520 | COMPOSITION FOR TREATING OR PREVENTING MILD COGNITIVE IMPAIRMENT - A composition for treating or preventing mild cognitive impairment is provided. The composition for treating or preventing mild cognitive impairment includes a compound having a structure represented by the formula I and an auxiliary component. In the formula I, R | 2022-08-11 |
20220249521 | USE OF DERIVATIVES CONTAINING C-O-P BONDS IN PATIENTS WITH KIDNEY FAILURE - Use of a derivative containing C—O—P bonds in a controlled release form to treat patients with kidney failure. Moreover, it comprises the use of said derivatives together with other active substances, which particularly may be selected from a list comprising a calcimimetic, vitamin, phosphate binder, thiosulfate, bisphosphonate, pyrophosphate, citrate, diuretic, antihypertensive and anticholesteraemic agent. | 2022-08-11 |
20220249522 | Hypoxia Targeting Compositions and Combinations Thereof with a PARP Inhibitor and Methods of Use Thereof - Methods for treating a cancer are provided, the methods comprising administering to an individual an effective amount of a hypoxia targeting composition, such as a hypoxia-activated drug or a prodrug thereof, and combinations thereof with an effective amount of a poly(ADP-ribose) polymerase (PARP) inhibitor. In some instances, one or more of a homology recombination (HR) efficiency status, an IDH mutation status, and a hypoxia status of a cancer is used as a basis for selecting an individual for a treatment disclosed herein. Also provided are compositions (such as pharmaceutical formulations), medicine, kits, and unit dosages useful for the methods described herein. | 2022-08-11 |
20220249523 | BENZOAZEPINE COMPOUND-CONTAINING FREEZE-DRIED COMPOSITION - A formulation stably comprising a tolvaptan prodrug is provided. Specifically, a freeze-dried composition comprising a compound represented by Formula (1): | 2022-08-11 |
20220249524 | Pharmaceutical formulations comprising 5-Chloro-N4-[2-(dimethylphosphoryl)phenyl]-N2-{2-methoxy-4-[4-(4-methylpi- perazin-1-yl)piperidin-1-yl]phenyl}pyrimidine-2,4-diamine - This invention relates to a pharmaceutical composition comprising 5-chloro-N4-[2-(dimethylphosphoryl)phenyl]-N2-{2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}pyrimidine-2,4-diamine as the active pharmaceutical ingredient, and therapeutic uses of the pharmaceutical formulation. In particular, the invention is directed to tablets comprising the pharmaceutical composition, methods of preparing the tablets, and therapeutic uses thereof. | 2022-08-11 |
20220249525 | Fatty Acid Compounds for Prevention and Treatment of Neurodegenerative Disorders - A fatty acid or fatty acid containing compound for use in the prevention and/or treatment of a neurodegenerative disorder, and related novel compounds. | 2022-08-11 |
20220249526 | HUMAN MILK OLIGOSACCHARIDES AND COMPOSITIONS THEREOF FOR USE IN PREVENTING, MANAGING OR TREATING SYMPTOMS RELATED TO MIGRAINE - The invention relates to a human milk oligosaccharide (HMO) for use in, a synthetic composition comprising an HMO for use in and a method for preventing, managing or treating postdrome symptoms of migraine, and/or abdominal migraine, and/or the secondary prevention of stress/anxiety induced migraine. | 2022-08-11 |
20220249527 | METHODS FOR REDUCING THE INCIDENCE OF OXIDATIVE STRESS USING HUMAN MILK OLIGOSACCHARIDES, VITAMIN C AND ANTI-INFLAMMATORY AGENTS - Disclosed are methods of reducing the incidence of oxidative stress in infants, toddlers, and children using nutritional compositions including human milk oligosaccharides. The nutritional compositions including the human milk oligosaccharides are effective at reducing inflammation and the incidence of inflammatory diseases. | 2022-08-11 |
20220249528 | AZACITIDINE IN COMBINATION WITH VENETOCLAX, GILTERITINIB, MIDOSTAURIN OR OTHER COMPOUNDS FOR TREATING LEUKEMIA OR MYELODYSPLASTIC SYNDROME - Provided herein are methods for using 5-azacytidine in combination with one or more additional agents to treat diseases and disorders including acute myeloid or myelogenous leukemia (AML). Other disease and disorders those associated with abnormal cell proliferation, myelodysplastic syndromes (MDS), abnormal cell proliferation, hematologic disorders, and immune disorders, among others. | 2022-08-11 |
20220249529 | AZACITIDINE IN COMBINATION WITH VENETOCLAX, GILTERITINIB, MIDOSTAURIN OR OTHER COMPOUNDS FOR TREATING LEUKEMIA OR MYELODYSPLASTIC SYNDROME - Provided herein are methods for using 5-azacytidine in combination with additional agents to treat diseases and disorders including AML. | 2022-08-11 |
20220249530 | METHOD AND COMPOSITION FOR PREVENTING AND TREATING VIRAL INFECTIONS - A method and composition for treating viral infections using a combination of naturally occurring compounds is provided. The method includes administering to a patient at risk of or diagnosed with a viral infection a composition including therapeutically effective amounts of a helicase ATPase inhibitor, a sialidase enzyme inhibitor, an ICAM-1 inhibitor and gallic acid which each also down regulate the immune response. The composition may further include a permeation enhancer. | 2022-08-11 |
20220249531 | TREATMENT OF P53-DEFICIENT CANCERS - Provided are methods and formulations for the treatment of p53-deficient cancers using a combinational drug strategy which enhances DNA damage in p53 deficient cells while not allowing cells to escape cell death by activation of p53-p21 signaling. Wild-type p53 carriers, on the other hand, respond with activation of p53-p21 signaling and cell-cycle arrest, thereby escaping cell death. The methods involve administering to an individual in need of treatment a combination of one or more poly (ADP ribose) polymerase inhibitors (PARPi) and one or more deoxyuridine analogs. Pharmaceutical formulations comprising PARPi and dU analogs are also provided. | 2022-08-11 |
20220249532 | COMBINATION THERAPY FOR HIV WITH ADENOSINE DERIVATIVE AND CAPSID INHIBITORS - The present disclosure is directed to methods of treating or preventing RNA virus infections and retroviral diseases, such as HIV and AIDS, comprising administering to a subject in need an effective amount of (a) a capsid inhibitor and (b) an adenosine derivative disclosed herein. Compositions comprising an effective amount of an adenosine derivative and an effective amount of a capsid (CA) inhibitor are also provided. | 2022-08-11 |
20220249533 | COMPOSITIONS AND METHODS FOR BONE REPAIR AND BONE HEALTH - The present disclosure relates to polymer-based biomaterials for the systemic or localized delivery of osteoanabolic molecules, and their use in methods for treating and/or preventing bone degeneration and for promoting bone regeneration. In one aspect, the present invention provides a biomaterial comprising a polymer and a bioactive molecule binding moiety. In certain embodiments of the first aspect of the invention, the bioactive molecule binding moiety is an osteoanabolic molecule binding moiety. | 2022-08-11 |
20220249534 | METHOD OF TREATING CANCER WITH NUCLEOTIDE THERAPEUTICS - The present disclosure provides methods for inhibiting cell proliferation, inducing differentiation, and inducing replication stress in a cancer cell. The present disclosure also provides methods for treating a cancer in a patient. Various methods of the disclosure include contacting a cancer cell with, or administering to a patient having cancer, an agent that can change the internal baseline ratio of purine:pyrimidine in the cancer cell. | 2022-08-11 |
20220249535 | COMPOSITIONS COMPRISING NICOTINAMIDE ADENINE DINUCLEOTIDE-RELATED COMPOUNDS AND USE THEREOF - The present disclosure relates to compositions comprising Nicotinamide Adenine Dinucleotide (NAD+)-related and precursor compounds, pharmaceutical compositions and kits containing them, and methods for using them. | 2022-08-11 |
20220249536 | ANTIBODY DRUG CONJUGATES - The present disclosure provides antibody drug conjugates comprising STING modulators. Also provided are compositions comprising the antibody drug conjugates. The compounds and compositions are useful for stimulating an immune response in a subject in need thereof. | 2022-08-11 |
20220249537 | Methods to Stabilize and Reverse Atherosclerotic Lesions by Sulfated Polysaccharides - A method of treating a vulnerable atherosclerotic plaque can include identifying the vulnerable atherosclerotic plaque and administering a sulfated polysaccharide, or a pharmaceutically acceptable salt thereof, to a subject in an amount and at a frequency sufficient to stabilize and reverse a vulnerable atherosclerotic plaque. | 2022-08-11 |
20220249539 | BOLAAMPHIPHILIC COMPOUNDS, COMPOSITIONS AND USES THEREOF - Bolaamphiphilic compounds are provided according to formula I: | 2022-08-11 |
20220249540 | INHALABLE COMPOSITION COMPROMISING CYCLODEXTRIN FOR USE IN THE TREATMENT OF NASAL INFLAMMATIONS - The present invention relates to an inhalable composition comprising cyclodextrin for the treatment of nasal inflammations. In a preferred embodiment, the treatment is topical. | 2022-08-11 |
20220249541 | POLYSACCHARIDE CARBON NANOGELS AND ANTICOAGULANTS AND ANTIOXIDANTS COMPRISING THE SAME - Provided is a nanogel exhibiting anticoagulation and antioxidation activities, including a graphene-like nanosheet and a polysaccharide, which are complexed to form a cross-linked supramolecular structure. Also provided is a method of preparing the nanogel, including carbonizing the polysaccharide by dry heating. By the heating process, at least a portion of the polysaccharide is conversed into the graphene-like nanosheet, thereby forming a graphene-like nanosheet-embedded phenolic-polysaccharide nanogel that has exceptional polyphenolic structure and high binding affinity toward thrombin. Further provided is a method of preventing or treating a disease or a condition susceptible to amelioration by anticoagulants or antioxidants by using the nanogel. | 2022-08-11 |
20220249542 | BOWEL CLEANSING CHEMICAL COMPOSITION AND ASSOCIATED USE THEREFORE - A GRAS list chemical composition (containing only GRAS list approved ingredients) including a water-based bowel cleansing solution (either in concentrate form or diluted form) to clean a gastrointestinal (GI) tract before and/or during performance of an endoscopy procedure such as a colonoscopy, enteroscopy, upper gastrointestinal endoscopy, and small bowel capsule endoscopy, for example. The GRAS list bowel cleansing chemical composition includes at least one of a chemical composition as a liquid, tablet or powder concentrate that can be added to sterile water or other solution by the end-user to make the chemical composition solution; and a pre-mixed chemical composition solution diluted in up to 1000 ml of sterile water. | 2022-08-11 |
20220249543 | Trona Based Therapeutic Compositions and Use and Manufacture Thereof - A method of treating a topical ailments can include identifying an ailment, procuring a therapeutic composition, and administering the therapeutic composition to a subject. More specifically, the ailment can be associated with a topical region of a subject. The therapeutic composition can be sterilized and include a sodium carbonate mineral and a carboxylic acid. The therapeutic composition can be administered to the topical region of the subject. | 2022-08-11 |
20220249544 | COMPOSITIONS OF NITRATES AND METHODS OF USE THEREOF - Inorganic anions nitrate and nitrite influence metabolic rate and glucose homeostasis. Infusion of nitrite iv caused an acute drop in resting energy expenditure (oxygen consumption) and nitrate, when given perorally, caused a reduction in oxygen consumption during exercise and a depression of the increase in blood glucose observed after an oral glucose tolerance test. The doses of nitrate and nitrite did not cause any detectable change in methemoglobin levels of blood. Also, nitrate and nitrite did not alter lactate levels in blood. This discovery provides useful treatments to regulate the energy expenditure and glucose homeostasis of a mammal by administration of inorganic nitrite and/or nitrate. | 2022-08-11 |
20220249545 | Platinum-Based Chemotherapy, Mast Binding Agents, Glucocorticoid Receptor (GR) Binding Agents, and/or HSP90 Binding Agents for Uses in Treating Cancer - This disclosure relates to methods of treating cancer comprising administering an effective amount of a platinum-based chemotherapy agent in combination with a microtubule associated serine/threonine-protein kinase (MAST) inhibitor and/or a glucocorticoid receptor binding agent and/or a hsp90 binding agent and/or other chemotherapy agents disclosed herein to a subject in need thereof. In certain embodiments, this disclosure relates to pharmaceutical compositions comprising combinations of agents disclosed herein and a pharmaceutically acceptable excipient. | 2022-08-11 |
20220249546 | BEVERAGE FORTIFIED WITH FERROUS BISGLYCINATE - The present invention relates generally to the field of beverages. In particular, the present invention relates to the field of beverages fortified with iron. For example, the present inventors have found that iron fortification with ferrous bisglycinate in a red plant based beverage with a pH in the range of 3.5 to 4.0 leads to an increased colour stability and a better taste of the beverage compared to other compounds commonly used to fortify beverages with iron. | 2022-08-11 |
20220249547 | METHOD OF PREVENTING COVID-19 INFECTION - A product for preventing COVID- | 2022-08-11 |
20220249548 | APPLICATION OF CARBON-BASED NANOMATERIAL IN PREPARATION OF DRUG FOR RELIEVING OR TREATING HD - Application of carbon-based nanomaterial in the preparation of drug for alleviating or treating HD. The carbon-based nanomaterial was prepared from the vitamin or quasi-vitamins. | 2022-08-11 |
20220249549 | ECM HYDROGEL FOR TREATING ESOPHAGEAL INFLAMMATION - Methods are disclosed for inhibiting esophageal inflammation in a subject, that include administering to the esophagus of the subject with esophageal inflammation a therapeutically effective amount of an extracellular matrix (ECM) hydrogel. Methods are also disclosed for reducing esophageal stricture. Compositions are disclosed that include an esophageal extracellular matrix (ECM) hydrogel. | 2022-08-11 |
20220249550 | PREPARATION AND USE OF TISSUE MATRIX DERIVED POWDER - Methods and applications of a lyophilized tissue matrix derived powder (TH Powder) are disclosed. The methods include improved approaches to viral and bacterial control, improved multi-stage grinding techniques and use of improved grinding systems. The TH powder produced using the disclosed methods includes properties, such as small powder particle sizes, nearly instant rehydration time, high solubility, flowability and injectability, and optionally short ( | 2022-08-11 |
20220249551 | STIMULATION OF NATURAL KILL CELL MEMORY BY ADMINISTRATION OF DENDRITIC CELLS - Disclosed are means, methods and compositions of matter useful for induction of natural killer cell memory by administration of dendritic cells and/or exosomes thereof. In one embodiment a mammal suffering from cancer is administered allogeneic cord blood derived dendritic cells that are not pulsed exogenously. In one embodiment the dendritic cells are stimulated to possess chemotactic activity towards the tumor by culture of dendritic cell progenitors in hypoxia. Natural killer cell memory is induced, in part, by triggering of upregulation of cytokines associated with homeostatic expansion such as interleukin 7 and interleukin 15. | 2022-08-11 |
20220249552 | CHIMERIC ANTIGEN RECEPTOR DENDRITIC CELL (CAR-DC) FOR TREATMENT OF CANCER - The current invention provides monocytic cells transfected with chimeric antigen receptor (CAR) to selectively home to tumors and upon homing differentiate into dendritic cells capable of activating immunity which is inhibitory to said tumor. In one embodiment of the invention, monocytic cells are transfected with a construct encoding an antigen binding domain, a transcellular or structural domain, and an intracellular signaling domain. In one specific aspect of the invention, the antigen binding domain interacts with sufficient affinity to a tumor antigen, capable of triggering said intracellular domain to induce an activation signal to induce monocyte differentiation into DC. | 2022-08-11 |
20220249553 | A COMPOSITION, A KIT AND USE THEREOF - The current invention relates to a composition for parenteral administration comprising a canine plasma and hyaluronic acid or a salt or ester thereof, wherein said plasma comprises lipids and/or phospholipids. The inventions also relates to a kit comprising one or more aliquots of a composition, said composition comprising a canine plasma comprising lipids and/or phospholipids and hyaluronic acid or a derivative thereof and optionally one or more pharmaceutical active ingredients, wherein said kit further comprises one or more aliquots of a calcium source, preferably a calcium chloride solution. The invention also pertains to the composition and kit of current invention for use in the treatment of musculoskeletal diseases. | 2022-08-11 |
20220249554 | COMPOSITIONS AND METHODS FOR MANAGING FEMALE INFERTILITY - The present disclosure provides for compositions and methods for managing female infertility, caused by diminished ovarian reserve. More particularly, the present disclosure provides a platelet rich plasma (PRP) having one or more of significantly higher platelet count and significantly low RBC and WBC count as compared to the starting blood, and a method to arrive at the same. Consequently, a growth factor concentrate derived from the PRP and a method to arrive at the same are provided. Further provided, along with therapeutic applications for treatment of infertility caused by diminished ovarian reserve are also provided. | 2022-08-11 |
20220249555 | EXPANDED NK CELL FRACTIONS FOR TRANSPLANTATION IN COMBINATION THERAPY - Methods of expanding a natural killer (NK) cell fraction for transplantation into a subject are provided, and particularly, methods for providing transplantable NK cell fractions and protocols for their use, which can be employed for applications in cell transplants and infusions, in particular, in combination therapy with anti-CD20 anti-cancer antibodies for treatment of cancer and other disease. | 2022-08-11 |
20220249556 | METHODS FOR TRANSDUCING IMMUNE CELLS - Provided herein are improved methods for transducing immune cells, such as T cells, with retroviral vectors to express exogenous gene products, such as chimeric antigen receptors (CARs). Provided herein are methods that increase transduction efficiency thereby increasing the percentage of immune cells in a population expressing the exogenous gene product. Associated cells, cell populations, compositions and methods of use are also provided. | 2022-08-11 |
20220249557 | Vaccine and Uses thereof in Cell Therapy - The present disclosure relates to compositions and methods for enhancing T cell response in vivo. For example, a method of enhancing T cell response in a subject or treating a subject having cancer, the method comprising: administering an effective amount of a composition comprising modified cells to the subject having a form of cancer associated with or expressing an antigen, for example, a solid tumor antigen; and administering (1) a nucleic acid encoding the antigen, (2) additional modified cells comprising the nucleic acid or the antigen, or (3) microorganisms, for example cold viruses, comprising the nucleic acid or the antigen. In embodiments, the modified cells comprise mixed cells targeting a solid tumor antigen and a white blood cell (WBC) antigen. In embodiments, the modified cells comprise a dominant negative form of an immune checkpoint molecule (e.g., PD-1). In embodiments, the modified cells comprise an exogenous polynucleotide encoding a therapeutic agent, such as IL-12 and IFNγ. | 2022-08-11 |
20220249558 | ALLOGENEIC CELL THERAPY OF B CELL MALIGNANCIES USING GENETICALLY ENGINEERED T CELLS TARGETING CD19 - A population of genetically engineered immune cells (e.g., T cells), which express a chimeric antigen receptor (CAR) specific to CD19 and contain a disrupted TRAC gene, a disrupted B2M gene, or both, for use in treating a B cell malignancy. | 2022-08-11 |
20220249559 | METHODS AND COMPOSITIONS FOR SELECTING TUMOR INFILTRATING LYMPHOCYTES AND USES OF THE SAME IN IMMUNOTHERAPY - The present invention provides improved methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for selecting TILs responsive to a mutant polypeptide expressed by cancer cells and not expressed in normal tissue. | 2022-08-11 |
20220249560 | CCR4 TARGETED CHIMERIC ANTIGEN RECEPTOR MODIFIED T CELLS FOR TREATMENT OF CCR4 POSITIVE MALIGNANCIES - Chimeric antigen receptors for use in treating lymphoma-associated C-C chemokine receptor type 4 (CCR4) and other cancers expressing CCR4 are described. | 2022-08-11 |
20220249561 | CHIMERIC ANTIGEN RECEPTOR-EXPRESSING CELLS TARGETING ALK - The present invention is intended to develop a chimeric antigen receptor (CAR) that is effective against solid tumor expressing anaplastic lymphoma kinase (ALK). The present invention provides a polynucleotide encoding a CAR protein comprising a target binding domain binding to an extracellular ligand binding region of ALK, a transmembrane domain, and an intracellular signaling domain. The target binding domain of the polynucleotide is selected from among FAM150A, FAM150B, and fragments thereof binding to the extracellular ligand binding region of ALK. The present invention also provides a genetically modified cell comprising the polynucleotide introduced thereinto. | 2022-08-11 |
20220249562 | TYPE III NKT CELLS AND RELATED COMPOSITIONS AND METHODS - The present disclosure relates to type III natural killer T (NKT) cells (e.g., CD3 | 2022-08-11 |
20220249563 | ANTI-DLL3 CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF - Provided herein are anti-DLL3 chimeric antigen receptors (CARs), DLL3 binding proteins and uses of such CARs or DLL3 binding proteins in the treatment of DLL3 associated disorders, such as small cell lung cancer. | 2022-08-11 |
20220249564 | PDL1 POSITIVE NK CELL CANCER TREATMENT - Provided herein are methods of treating cancer in a subject including detecting an amount of PD-L1(+) natural killer (NK) cells in a biological sample from the subject and treating the subject with an anti cancer therapy. Provided herein are methods of treating cancer in a patient including isolating natural killer (NK) cells from a subject, producing a population of PD-L1(+) NK cell from the isolated NK cells, and administering the population of PD-L1(+) NK cells into the patient. | 2022-08-11 |
20220249565 | CHIMERIC ANTIGEN RECEPTOR WITH 4-IBB COSTIMULATORY DOMAIN - Provided are CAR-T compositions that are directed to a CAR including (i) an extracellular domain comprising an antigen-binding domain; (ii) a transmembrane domain; and (iii) an intracellular domain comprising a costimulatory endodomain, wherein the costimulatory endodomain comprises an intracellular signaling domain from 4-1BB/CD137 and five additional amino acids. The disclosure also provides vectors, compositions, and methods of treatment using the antigen binding molecules and engineered immune cells comprising the CAR. The CAR compositions provided herein can be used for the treatment of certain cancers. | 2022-08-11 |
20220249566 | VIRUS-LIKE PARTICLE - The present invention provides a virus-like particle (VLP) having a viral envelope which comprises: (i) a membrane protein comprising the extracellular domain of CD86; and (ii) a CD3-binding membrane protein. The VLP may be used to activate T cells prior to viral transduction. | 2022-08-11 |
20220249567 | LOW DENSITY CELL CULTURE - A method of producing a collection of natural killer cells from CD34 | 2022-08-11 |
20220249568 | Combined chimeric antigen receptor targeting CD19 and CD20 and application thereof - The present invention provides a combined chimeric antigen receptor targeting CD19 and CD20 and application thereof. Specifically, the present invention provides a combined chimeric antigen receptor targeting CD19 and CD20, which comprises a scFv targeting CD19 and CD20, a hinge region, a transmembrane region, and an intracellular signaling domain. The present invention provides a nucleic acid molecule encoding the chimeric antigen receptor and a corresponding expression vector, a CAR-T cell, and applications thereof. The experimental results show that the chimeric antigen receptor provided by the present invention shows extremely high killing ability against tumor cells. The chimeric antigen receptor of the present invention targets CD19 and/or CD20 positive cells and can be used to treat CD19 and/or CD20 positive B-cell lymphoma, leukemia and other diseases. | 2022-08-11 |
20220249569 | ORGANOIDS COMPRISING ISOLATED RENAL CELLS AND USES THEREOF - Described herein are organoids comprising admixtures of selected bioactive primary renal cells and a bioactive cell population, e.g., an endothelial cell populations, e.g. HUVEC cells, and methods of treating a subject in need thereof with such organoids. Further, the isolated renal cells, which may include tubular and erythropoietin {EPO}-producing kidney cell populations, and/or the endothelial cell populations may be of autologous, syngeneic, allogeneic or xenogeneic origin, or any combination thereof. Further provided are methods of treating a subject in need with the organoids. | 2022-08-11 |
20220249570 | NANOVESICLES FROM ADULT STEM CELLS AND ITS USE FOR TARGETED THERAPY - Disclosed herein is a nanovesicles from adult stem cells containing iron nanoparticles and its use. The nanovesicle according to the present disclosure provides effects of maximizing the efficacy of treating mesenchymal stem cells by pretreating cells with iron nanoparticles; reconstituting the cells in a nano-sized form to facilitate intravenous injection; and increasing the efficiency of targeting disease areas through magnet induction. In particular, the present disclosure can replace mesenchymal stem cells as a cell therapeutic agent, and it can be applied to various diseases as a novel biopharmaceutical drug because it can increase the function and efficiency of an exosome-based therapeutic agent. | 2022-08-11 |
20220249571 | NEOINTIMA FORMATION USING MESENCHYMAL STEM CELLS OR DERIVATIVES THEREOF - This disclosure relates to methods for treating vascular conditions using mesenchymal stem cells or a derivate thereof. In particular, this disclosure relates to methods for facilitating neointima formation over an endovascular device or vascular graft through administration of mesenchymal stems cells or a derivate thereof. | 2022-08-11 |
20220249572 | Composite Including Neural Retina, Retinal Pigment Epithelial Cells, and Hydrogel, and Method for Producing Same - Provided is a composite comprising a neural retina, a retinal pigment epithelial cell sheet, and a hydrogel. | 2022-08-11 |
20220249573 | CARTILAGE REGENERATION USING CHONDROCYTE AND TGF-BETA - The present application is directed to a method of treating osteoarthritis, which includes obtaining a member of a transforming growth factor superfamily of proteins; obtaining a population of cultured mammalian cells that may contain vector encoding a gene, or a population of cultured connective tissue cells that do not contain any vector encoding a gene; and then transferring the protein and the connective tissue cells into an arthritic joint space of a mammalian host, such that the activity of the combination within the joint space results in regenerating connective tissue. | 2022-08-11 |
20220249574 | ADIPOSE TISSUE-DERIVED STROMAL STEM CELLS FOR USE IN TREATING REFRACTORY COMPLEX PERIANAL FISTULAS IN CROHN'S DISEASE - Provided herein are expanded allogeneic adipose tissue-derived stromal stem cells for use in treating complex perianal fistulas in Crohn's Disease. | 2022-08-11 |
20220249575 | FORMULATION AND TREATMENT FOR OPHTHALMIC DISORDERS - The disclosure provides therapeutic ophthalmic formulations, kits, and uses thereof in the treatment of eye pathologies. | 2022-08-11 |
20220249576 | METHOD OF DISRUPTING MYCOTOXIN SYNTHESIS USING A COMPOSITION COMPRISING VIBRIO GAZOGENES - A method of inhibiting mycotoxin synthesis in filamentous fungi comprises contacting the filamentous fungi with a composition comprising | 2022-08-11 |
20220249577 | METHODS AND COMPOSITIONS FOR CONTROLLING OR REDUCING PESTS - The present invention relates to methods and compositions comprising viable spores of | 2022-08-11 |
20220249578 | COMPOSITIONS AND METHODS FOR INHIBITION OF PATHOGENIC BACTERIAL GROWTH - Compositions for methods of preventing or reducing pathogenic bacterial growth, proliferation, and/or colonization are described containing one or more types of non-pathogenic bacteria to be introduced into the gastrointestinal tract and effectively compete with pathogenic bacteria for monomeric or polymeric carbohydrate nutrients, and/or amino acid nutrients, and/or vitamin nutrients. | 2022-08-11 |
20220249579 | SECRETED MICROBIAL EXTRACELLULAR VESICLES - Provided herein are methods and pharmaceutical compositions related to secreted microbial extracellular vesicles (smEVs) that can be useful as therapeutic agents. | 2022-08-11 |
20220249580 | PROBIOTIC COMPOSITIONS AND USES THEREOF - The present invention relates to an isolated bacterial strain of | 2022-08-11 |
20220249581 | COMPOSITION FOR PREVENTION OR TREATMENT OF METABOLIC DISORDERS OR MUSCULAR DISEASES COMPRISING EXTRACELLULAR VESICLES DERIVED FROM LACTOBACILLUS BACTERIA - Provided is a composition for preventing or treating a metabolic disease or muscle disease, which includes vesicles derived from bacteria of the genus | 2022-08-11 |
20220249582 | GABA-PRODUCING CULTURABLE BACTERIA AND USE FOR IMPROVING HEALTH - A composition for use in a method of regulating or treating a metabolic disease or a symptom thereof, the composition comprising an isolated bacteria | 2022-08-11 |
20220249583 | NOVEL LACTIC ACID BACTERIA STRAIN - ANTIBACTERIAL PEPTIDES PRODUCED BY SAID STRAIN AND RELATED PHARMACEUTICAL COMPOSITIONS | 2022-08-11 |
20220249584 | SECOND GENERATION SENECA VALLEY VIRUS ONCOLYTIC THERAPY: COMPOSITIONS AND METHODS THEREOF - Provided herein are compositions and methods of using Seneca Valley Virus (SVV) or a derivative thereof and an interferon type I (IFN-I) inhibiting agent comprising an mTOR inhibitor for treating a cancer in a subject. The disclosed methods particularly rely upon the expression level of an ANTXR1 and the expression level of IFN-I in the cancer from the subject. Also provided herein are methods for predicting the efficacy of an SVV treatment comprising IFN-I inhibiting agent. | 2022-08-11 |
20220249585 | MEDICATION COATED WITH HEMP OR OTHER CANNABINOID - A medication comprising a medication coated with hemp, or a composition including hemp oil, hemp seed oil, or another cannabinoid is provided. | 2022-08-11 |
20220249586 | HEMP EXTRACT AND METHODS OF USE THEREOF - The present disclosure relates to methods of treating periuria, diabetes, lung cancer, inflammatory bowel disease, dermatological conditions, seizures, obsessive behaviors, migraine headaches, or insect bites in subjects using pharmaceutical compositions and dosage forms comprising hemp extract. | 2022-08-11 |
20220249587 | ANTI-INFLUENZA VIRUS COMPOSITION, COMPOSITION FOR TREATING RESPIRATORY DISEASES, AND ANTI-AGING COMPOSITION, COMPRISING DARK GINSENG EXTRACT - The present invention relates to an anti-influenza virus composition, a composition for treating respiratory diseases, and an anti-aging composition, each of which comprises a dark ginseng extract. | 2022-08-11 |
20220249588 | METHODS FOR MAKING BOTANICAL EXTRACT COMPOSITION - A method for making a caffeoylquinic composition from a botanical source is disclosed. The method may include chromatographing an extract of biomass on an ion exchange stationary phase and obtaining an eluent comprising a caffeoylquinic composition. The biomass may be stevia or yerba mate, for example. The caffeoylquinic composition includes one or more of monocaffeoylquinic acid, dicaffeoylquinic acid, and salts of the foregoing. | 2022-08-11 |
20220249589 | HERB MEDICINE COMPOSITION FOR ALLEVIATING OR TREATING ASTHMA, AND ORIENTAL PHARMACOPUNCTURE SOLUTION CONTAINING SAME AND INJECTION CONTAINING SAME - A composition for alleviating or treating asthma is proposed. A composition for alleviating or treating asthma contains, as an active ingredient, a concentrate obtained by distilling an extract obtained by extracting a herb medicine complex containing dried | 2022-08-11 |
20220249590 | EFFICACY OF GARLIC THERAPY IN CONTROLLING INFLAMMATORY CYTOKINES AND CARTILAGE DEGRADATION IN KNEE OSTEOARTHRITIS AND IMPROVING QUALITY OF LIFE - Methods for treating knee osteoarthritis in a patient are disclosed. In one embodiment, a method for treating a knee osteoarthritis patient using an oral dried garlic supplement, wherein the treating comprises administering 900 mg of the oral dried garlic supplement on a daily basis. In one embodiment, 1800 mg of the oral dried garlic supplement is used. | 2022-08-11 |
20220249591 | COMPOSITION FOR THE TREATMENT OF EMOTIONAL DISORDERS - The present invention relates to a composition comprising glutamine, | 2022-08-11 |
20220249592 | MUSCLE QUALITY IMPROVEMENT AGENT - Agents containing γ-glutamyl peptide can prevent a decline in muscle quality and improve muscle quality even when exercise is limited, and further, can effectively enhance the effect of exercise even when the exercise is of a level free of undue efforts. | 2022-08-11 |